Market news Latest

Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast – 2030

 Breaking News
  • No posts were found

Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast – 2030

April 08
08:47 2020
Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast - 2030

DelveInsight has launched a new report on Fragile X Syndrome Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “Fragile X Syndrome (FXS) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Fragile X Syndrome (FXS) , historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fragile X Syndrome (FXS) market report provides current treatment practices, emerging drugs, Fragile X Syndrome (FXS) market share of the individual therapies, current and forecasted Fragile X Syndrome (FXS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fragile X Syndrome (FXS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hyper- methylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. It is actually considered as the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. The clinical spectrum of FXS is wide, presenting not only as an isolated intellectual disability but as a multi-systemic condition, involving predominantly the central nervous system but potentially affecting any apparatus. Individuals with FXS present with intellectual disability, autism, hyperactivity, long face, large or prominent ears, and macroorchidism at puberty and thereafter. Most of the young children with FXS will present with language delay, sensory hyperarousal and anxiety.

 

Request for :- Free sample page

Epidemiology

The Fragile X Syndrome (FXS) epidemiology division provide insights about historical and current Fragile X Syndrome (FXS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Reports key facts:- 

1. As per DelveInsight estimates, total cases of Fragile X Syndrome (FXS) in the 7MM was found to be 117,962 in 2017. Among all the countries, the estimates show highest population of FXS in the United States with 67,654 cases in 2017.

2. Among the EU5 countries, Germany had the highest diagnosed prevalent population of FXS with 9,383 cases, followed by France. On the other hand, Spain had the lowest prevalent population

3. The Age-specific cases were divided into 0-11, 12-17 and 18 and above years of age. As per our estimate, in US, 29,463 cases belong to 0-11 in 2017.

Key companies are working on this disease that are given below:- 

1. Zynerba Pharmaceuticals Co.
2. Confluence Pharmaceuticals Co.
3. Tetra Therapeutics

Name of drugs covered that are given below:-

1. Cannabidiol
2. Acamprostate
3. BPN14770

Table of contents

1. Key Insights

2. Executive Summary of Fragile X Syndrome (FXS)

3. Competitive Intelligence Analysis for Fragile X Syndrome (FXS)

4. Fragile X Syndrome (FXS) : Market Overview at a Glance

4.1. Fragile X Syndrome (FXS) Total Market Share (%) Distribution in 2017

4.2. Fragile X Syndrome (FXS) Total Market Share (%) Distribution in 2030

5. Fragile X Syndrome (FXS) : Disease Background and Overview

6. Patient Journey

7. Fragile X Syndrome (FXS) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Fragile X Syndrome (FXS) Treatment and Management

8.2. Fragile X Syndrome (FXS) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Fragile X Syndrome (FXS) Treatment

11. Marketed Products

12. Emerging Therapies

13. Fragile X Syndrome (FXS) : Seven Major Market Analysis

13.1. Key Findings

13.2. Fragile X Syndrome (FXS) Market Size in 7MM

13.3. Fragile X Syndrome (FXS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Fragile X Syndrome (FXS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome (FXS) market
  • To understand the future market competition in the Fragile X Syndrome (FXS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) market
  • To understand the future market competition in the Fragile X Syndrome (FXS) market

Related Reports:- 

1. Fragile X Syndrome (FXS) – Epidemiology Forecast to 2030

2. Fragile X Syndrome – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/